Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease

Imagem de Miniatura
Arquivos
art_SANTOS_Statin_Use_Is_Not_Associated_With_Presence_of_2014.PDF (186.47 KB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
ONI, Ebenezer T.
SINHA, Pragya
KARIM, Adil
MARTIN, Seth S.
BLAHA, Michael J.
AGATSTON, Arthur S.
BLUMENTHAL, Roger S.
MENEGHELO, Romeu S.
CONCEICAO, Raquel D.
Citação
ARCHIVES OF MEDICAL RESEARCH, v.45, n.1, p.52-57, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background and Aims. There is concern that statin use may exacerbate nonalcoholic fatty liver disease (NAFLD). We aimed to assess the association of statin use with NALFD and severity of liver fibrosis among NAFLD individuals. Methods. We evaluated 6,385 cross-sectional healthy Brazilian subjects (43 +/- 10 years, 79% males) without clinical coronary heart disease between November 2008 and July 2010. NAFLD was diagnosed by ultrasound. Severity of liver fibrosis was predicted by fatty liver index and FIB-4. Results. NAFLD prevalence was 36% (n = 2310). Overall 552 (9%) individuals were using statins of whom 49% had NAFLD. Statin users were more likely to be men, older age, and have higher burden of risk factors (p <0.05). In age gender adjusted analysis the odds ratio for NAFLD with statin use was 0.87 (0.61-1.25, p = 0.46) in the presence of metabolic syndrome and 1.08 (0.88-1.32, p = 0.56) in its absence. On further adjustment for metabolic risk factors, LDL and smoking the results remained unchanged (OR: 0.89; 95% CI: 0.65-1.32, p = 0.56 and 0.90 (0.69-1.18, p = 0.46). There was no significant association between statin use and fatty liver index in a subanalysis of NAFLD individuals (71 18 vs. 69 23, p = 0.18). Although FIB-4 was mildly elevated with statin use (1.20 +/- 0.51 vs. 1.02 +/- 0.46, p <0.001), a multivariate analysis adjusted for age, gender and risk factors revealed statin use was not associated with severe fibrosis (FIB >1.45) (OR 0.88, 95% CI: 0.60-1.29, p = 0.50). Conclusions. The results of this study favor statin use in subjects with NAFLD as its use is not associated with the presence of NAFLD or increased fibrosis (C) 2014 IMSS.
Palavras-chave
Statins, NAFLD, Fatty Liver Index, FIB-4 index, Fibrosis
URI
https://observatorio.fm.usp.br/handle/OPI/5347
Referências
  1. Abel T, 2009, MED SCI MONITOR, V15, pMS6
  2. Adams LA, 2005, DIABETIC MED, V22, P1129, DOI 10.1111/j.1464-5491.2005.01748.x
  3. Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775
  4. Antonopoulos S, 2006, ATHEROSCLEROSIS, V184, P233, DOI 10.1016/j.atherosclerosis.2005.08.021
  5. Athyros VG, 2010, LANCET, V376, P1916, DOI 10.1016/S0140-6736(10)61272-X
  6. Bader T, 2010, AM J GASTROENTEROL, V105, P978, DOI 10.1038/ajg.2010.102
  7. Bader T, 2010, LANCET, V376, P1882, DOI 10.1016/S0140-6736(10)62142-3
  8. Bellentani S, 2000, ANN INTERN MED, V132, P112
  9. Bhatia LS, 2012, CURR OPIN CARDIOL, V27, P420, DOI 10.1097/HCO.0b013e328354829c
  10. Bhatia LS, 2012, EUR HEART J, V33, P1190, DOI 10.1093/eurheartj/ehr453
  11. Cappellari M, 2013, NEUROLOGY, V80, P655, DOI 10.1212/WNL.0b013e318281cc83
  12. Chalasani N, 2005, HEPATOLOGY, V41, P690, DOI 10.1002/hep.20671
  13. Charles EC, 2005, AM J MED, V118, P618, DOI 10.1016/j.amjmed.2005.02.008
  14. Cohen DE, 2006, AM J CARDIOL, V97, p77C, DOI 10.1016/j.amjcard.2005.12.014
  15. Eidelman RS, 2002, ARCH INTERN MED, V162, P2033, DOI 10.1001/archinte.162.18.2033
  16. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP), 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/JAMA.285.19.2486
  17. Foster T, 2011, AM J GASTROENTEROL, V106, P71, DOI 10.1038/ajg.2010.299
  18. Fraser A, 2007, ARTERIOSCL THROM VAS, V27, P2729, DOI 10.1161/ATVBAHA.107.152298
  19. Gomez-Dominguez E, 2006, ALIMENT PHARM THERAP, V23, P1643, DOI 10.1111/j.1365-2036.2006.02926.x
  20. Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
  21. Hyogo H, 2011, HEPATOL RES, V41, P1057, DOI 10.1111/j.1872-034X.2011.00849.x
  22. Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161
  23. Marchesini G, 2005, CURR OPIN LIPIDOL, V16, P421, DOI 10.1097/01.mol.0000174153.53683.f2
  24. McCullough AJ, 2006, J CLIN GASTROENTEROL, V40, pS17
  25. Mihaila RG, 2009, HEPATO-GASTROENTEROL, V56, P1117
  26. Minder CM, 2013, CURR OPIN CARDIOL, V28, P554, DOI 10.1097/HCO.0b013e32836429e6
  27. Musso G, 2011, CURR OPIN LIPIDOL, V22, P489, DOI 10.1097/MOL.0b013e32834c37ee
  28. Ndumele CE, 2011, ARTERIOSCL THROM VAS, V31, P1927, DOI 10.1161/ATVBAHA.111.228262
  29. Nelson A, 2009, J CLIN GASTROENTEROL, V43, P990, DOI 10.1097/MCG.0b013e31819c392e
  30. Neuschwander-Tetri BA, 2005, AM J MED SCI, V330, P326, DOI 10.1097/00000441-200512000-00011
  31. Nseir W, 2012, DIGEST DIS SCI, V57, P1773, DOI 10.1007/s10620-012-2118-3
  32. Nseir W, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-012-0305-5
  33. Nseir W, 2011, DIGEST DIS SCI, V56, P3439, DOI 10.1007/s10620-011-1767-y
  34. PERLOFF D, 1993, CIRCULATION, V88, P2460
  35. Rallidis Loukianos S., 2004, Atherosclerosis, V174, P193, DOI 10.1016/j.atherosclerosis.2004.01.008
  36. Saadeh S, 2002, GASTROENTEROLOGY, V123, P745, DOI 10.1053/gast.2002.35354
  37. Shah RV, 2012, CIRCULATION, V126, pE282, DOI 10.1161/CIRCULATIONAHA.112.122135
  38. Sumida Y, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-2
  39. Tandra Sweta, 2009, Curr Treat Options Cardiovasc Med, V11, P272

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - ODS/03